Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Skip to main content

Growth Equity

China’s rise up the industrial value chain is creating a structural challenge for Europe. Our Chart Of The Week comes from Jeremie Peloso, Chief European Strategist. China shock 1.0 largely benefited Europe. China supplied cheap labor and low value added…
Our portfolio construction strategists are long the aesthetics theme, favoring GLP-1 producers, biostimulator injectables, and K-Beauty contract manufacturers. Remote work, online dating, and demographic change have raised the premium on appearance, while…
Special Report

The rise of remote work, online dating, and other demographic changes are increasing the demand for aesthetics. GLP-1s provide an effective and inexpensive cure for obesity, and their secondary effect “Ozempic face” has structurally altered the demand for aesthetic procedures and skincare. Long GLP-1 producers, biostimulator injectable producers, and K-Beauty contract manufacturers.

Growth, inflation, and rate risk drive sector returns and fundamentals, but macro’s explanatory power is at multi-decade lows. Long/short industry-group baskets show the equity market has turned pessimistic about growth, a potential opportunity as the macro data firm. The market’s inflation view has climbed, a move that may be harder to fade given rising oil prices. 

We are turning more constructive on Chinese internet stocks after several years of caution. We recommend going long offshore internet equities in absolute terms and upgrading MSCI China to overweight in a global equity portfolio.